Recent Updates
Recently added Catalysts

Descartes-11

Phase 2

Multiple Myeloma | Biologics | Oncology |Cartesian Therapeutics, Inc.|Trials Updated: Dec 3, 2024

Descartes-11 development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Jun 2019

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment5

FDA Designations

No designations recorded

Descartes-11 clinical trials

Descartes-11 · 1 trial · 1 indication

Phase 2 1
NCT04436029Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction TherapyMultiple Myeloma
COMPLETED5 Analytics
PHASE2COMPLETED
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Multiple MyelomaUnlock trial analytics

Study Endpoints

Primary Endpoints

Rate of Stringent Complete Response
1 year

Per IMWG 2016 Response Criteria Summary sCR: Complete response (CR) plus a normal free light chain ratio and no clonal cells in bone marrow (by immunohistochemistry). The FLC ratio must be Kappa/Lambda ≤ 4:1 or ≥ 1:2 after counting at least 100 plasma cells. CR: Negative immunofixation in serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% plasma cells in bone marrow. VGPR: Serum M-protein detectable by immunofixation (not on electrophoresis) or a ≥ 90% reduction in M-protein, with urine M-protein \<100 mg/24 hours. PR: ≥ 50% reduction in serum M-protein and a ≥ 90% reduction in 24-hour urinary M-protein (or to \<200 mg/24 hours). If M-protein is unmeasurable, a ≥ 50% decrease in the difference between involved and uninvolved FLC levels is required. If both M-protein and serum-free light chains are unmeasurable, a ≥ 50% reduction in plasma cells is necessary, provided baseline plasma-cell percentage in bone marrow was ≥ 30%. Overall Response (OR): CR+VGPR+PR

Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Descartes 11EXPERIMENTAL -

Interventions

NameTypeDescription
Descartes 11BIOLOGICALCar T-cells
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites4

Inclusion Criteria: * Patients must be 18 years of age or older at the time of enrollment * High-risk multiple myeloma patients who complete pre-transplant induction treatment anti- myeloma drug combination (minimum 2 drugs). Exclusion Criteria: * Patients who are pregnant or lactating. * Patient...

Countries:United States
Unlock Eligibility Criteria

Competitive Landscape -Multiple Myeloma 338 trials

Unlock Competitive Intelligence

Frequently asked questions about Descartes-11

What is Descartes-11 used for?

Descartes-11 is an investigational biologic being studied for high-risk multiple myeloma. Specifically, it is being evaluated as consolidation treatment in patients who have residual disease after induction therapy. It is in Phase 2 clinical development and is not approved for any use.

Who is developing Descartes-11?

Descartes-11 is being developed by Cartesian Therapeutics, Inc., which trades under the ticker RNAC. The company is advancing the asset in oncology, with multiple myeloma as its lead indication for this program.

What phase is Descartes-11 in?

Descartes-11 is in Phase 2 clinical development. It is an investigational therapy and has not been approved by the FDA. Its clinical program in high-risk multiple myeloma consists of one completed Phase 2 trial.

What clinical trials is Descartes-11 in?

Descartes-11 has been studied in one Phase 2 trial, NCT04436029, titled Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy. The trial was conducted in the United States, enrolled 5 patients, and is now completed.

Is Descartes-11 the same as Descartes 11?

Yes, Descartes-11 and Descartes 11 refer to the same investigational therapy. The hyphenated form Descartes-11 is the standard spelling used by Cartesian Therapeutics, while Descartes 11 is a common alternate rendering used in searches and references to the same multiple myeloma program.

How was the Descartes-11 trial designed?

The Phase 2 trial NCT04436029 was an uncontrolled, open-label study without randomization or blinding. It enrolled 5 patients aged 18 years and older of all sexes, all with high-risk multiple myeloma and residual disease following induction therapy, and it did not use biomarker-based patient selection.